Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Veeva (VEEV) to $333 from $341 and keeps an Overweight rating on the shares. The firm cites lower comparable multiples, offset somewhat by raised estimates. Despite the decremental optics from more CRM takeaways, Veeva’s product-led growth narrative is strengthening with valuation near trough levels, Wells adds.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Buy Rating Affirmed Amid Growth Potential and Strategic Advancements
- Oppenheimer says Roche’s commitment to Veeva Vault CRM carries greater weight
- Veeva announces expanded partnership with Roche Pharmaceuticals
- Veeva price target lowered to $319 from $349 at Citi
- Veeva Systems Inc. Earnings Call Highlights Growth and Challenges